Myasthenia gravis is an autoimmune neurological disorder caused by autoantibodies against the acetylcholine receptor or against a receptor-associated protein, muscle-specific tyrosine kinase (MuSK-Ab).
The autoimmune attack at the muscle endplate leads to failure of neuromuscular transmission and eventually muscle weakness.
In the active phase of the disease, symptoms typically fluctuates and then become severe; myasthenic crisis occur in this phase.
In the stable/inactive phase, symptoms are stable but still persist; it usually worsen attributable to infection, fatigue, tapering of medications or other identifiable factors.
In the burnt-out phase, remission may occur wherein patients are on immunotherapy and symptom-free, or may even be off medications.
In 15-20 years, if the symptoms left untreated, patient's weakness becomes fixed wherein the most severely affected muscles become atrophic.
Benatar M, Kaminski HJ; Quality Standards Subcommittee of the American Academy of Neurology. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2007 Jun;68(24):2144-2149. PMID: 17460154
Chaudhry V, Cornblath DR, Griffin JW, et al. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology. 2001 Jan;56(1):94-96. PMID: 11148242
Gajdos P, Chevret S, Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev. 2006 Apr(2):CD002277. PMID: 16625559
Ciafaloni E, Massey JM, Tucker-Lipscomb B. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology. 2001 Jan;56(1):97-99. PMID: 11148243
Mantageeza R, Bonanno S, Camera G, Antozzi C. Current and emerging therapies for the treatment of myasthenia gravis. Neuropsychiatr Dis Treat. 2011;7:151-160. PMID: 21552317
Gronseth GS, Barohn RJ. Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000 Jul;55(1):007-15. PMID: 10891896
Bird SJ. Clinical manifestations of myasthenia gravis. UpToDate. http://www.uptodate.com/contents/clinical-manifestations-of-myasthenia-gravis. 30 Jun 2011. Accessed 30 May 2012
Bird SJ. Treatment of myasthenia gravis. UpToDate. http://www.uptodate.com/contents/treatment-of-myasthenia-gravis. Aug 2015. Accessed 30 May 2012.
Bird SJ. Diagnosis of myasthenia gravis. UpToDate. http://www.uptodate.com/contents/diagnosis-of-myasthenia-gravis. 07 Apr 2011. Accessed 30 Mar 2012
Gold R, Hohlfeld R, Toyka KV. Progress in the treatment of myasthenia gravis. Ther Adv Neurol Disord. 2008 Sep;1(2):36-51. doi: 10.1177/1756285608093888. PMID: 21180568
Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016 Jul;87(4):419-425. doi: 10.1212/WNL.0000000000002790. PMID: 27358333
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).